Lacosamide Sugar Free Alissa

Lacosamide, the active ingredient in Lacosamide Sugar Free Alissa, is a sodium channel blocker presented as an oral formulation for oral use. It treats partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Sugar Free Alissa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that modulates neuronal sodium channels in epilepsy.

- Partial‑onset seizures: reduces seizure frequency and severity. - Adjunct therapy in epilepsy: improves overall seizure control when combined with other antiepileptics. - Focal epilepsy: provides additional reduction in seizure episodes.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Nausea: mild gastrointestinal upset. - Headache: occasional tension‑type headache. - Fatigue: increased tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal ideation: emergence of depressive thoughts or self‑harm tendencies. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: alterations in heart rhythm, especially in patients with pre‑existing conduction disorders. - Respiratory depression: marked reduction in breathing effort. - Hypersensitivity reactions: including anaphylaxis or severe rash. - Elevated liver enzymes: indicating potential hepatic stress.

Before prescribing Lacosamide, clinicians should consider several safety factors.

- Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: monitor liver function and consider dose modification. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Concomitant CNS depressants: monitor for enhanced sedation or dizziness. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce lacosamide plasma levels. - Other sodium channel blockers (e.g., lamotrigine, phenytoin): increase risk of CNS depression and cardiac effects. - QT‑prolonging agents (e.g., quinidine, sotalol): may exacerbate arrhythmia risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: lacosamide may decrease hormonal efficacy; consider alternative contraception. - Alcohol: combined use can enhance dizziness and sedation. - Additional antiepileptics: dose adjustments may be needed to maintain therapeutic balance.